• Value Research Rating market-capitalisation-info
    Not Applicable
  • Market Capitalisation market-capitalisation-info $12 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-252 Mln

Clovis Oncology Inc. (CLVS) Share Price

$0.09

As on 22-Feb-2023 09:30 EST

up-down-arrow $0.003.33%

  • Prev Close info

    $0.09

  • Day's Openinfo

    $0.08

  • Today's Highinfo

    $0.10

  • Today's Lowinfo

    $0.08

  • Today's Volumeinfo

    361,782

  • 52 Week rangeinfo

    $-- - --

Please wait...

Clovis Oncology Inc. (CLVS) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Clovis Oncology (CLVS)
76.47 -38.45 -73.43 -94.56 -79.63 -72.09 -41.15
S&P BSE Sensex*
2.08 2.78 10.09 25.07 14.52 15.51 13.32
#
-- -- -- -- -- -- --
As on 22-Feb-2023  |  *As on 01-Mar-2024  |  #As on
2022
2021
2020
2019
2018
2017
2016
Clovis Oncology (CLVS)
-98.06 -43.54 -53.96 -41.95 -73.40 53.08 26.91
S&P BSE Sensex
4.44 21.99 15.75 14.38 5.87 27.91 1.95
S&P BSE Sensex
4.44 21.99 15.75 14.38 5.87 27.91 1.95

Valuation Score

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Clovis Oncology Inc. (CLVS) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Clovis Oncology Inc. (CLVS)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Clovis Oncology Inc. (CLVS)

        Co-Founder, CEO, Pres & Exec. Director

        Mr. Patrick J. Mahaffy MA

        Exec. VP & CFO

        Mr. Daniel W. Muehl

        Headquarters

        Boulder, CO

        FAQs for Clovis Oncology Inc. (CLVS)

        The total asset value of Clovis Oncology Inc. (CLVS) stood at $ 1,095 Mln as on 30-Sep-22

        The share price of Clovis Oncology Inc. (CLVS) is $0.09 (NASDAQ) as of 22-Feb-2023 09:30 EST. Clovis Oncology Inc. (CLVS) has given a return of -79.63% in the last 3 years.

        Clovis Oncology Inc. (CLVS) has a market capitalisation of $ 12 Mln as on 22-Feb-2023. As per Value Research classification, it is a company.

        Since, TTM earnings of Clovis Oncology Inc. (CLVS) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Clovis Oncology Inc. (CLVS) and enter the required number of quantities and click on buy to purchase the shares of Clovis Oncology Inc. (CLVS).

        Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3);and FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. In addition, the company sells its Rubraca through a limited number of specialty distributor and specialty pharmacy providers, who subsequently sells Rubraca to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, a clinical collaboration with Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado. On December 11, 2022, Clovis Oncology, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

        The CEO & director of Mr. Patrick J. Mahaffy MA. is Clovis Oncology Inc. (CLVS), and CFO & Sr. VP is Mr. Daniel W. Muehl.

        The promoters of Clovis Oncology Inc. (CLVS) have pledged 0% of the total equity as on Sep-22.

        Clovis Oncology Inc. (CLVS) Ratios
        Return on equity(%)
        --
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0
        Dividend yield(%)
        0

        No, TTM profit after tax of Clovis Oncology Inc. (CLVS) was $-252 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $11.77 Mln
        • Revenue (TTM)revenue-information $133.02 Mln
        • Earnings (TTM) earning-information $-251.90 Mln
        • Cash date-information $58.32 Mln
        • Total Debt info $458.57 Mln
        • Insider's Holding 1.44%
        • Liquidity liquidity
        • 52 Week range week-range $-- - --
        • Shares outstanding share-outstanding 144,955,008
        • 10 Years Aggregate:

          CFO: $-2,173.19 Mln

          EBITDA: $-2,676.93 Mln

          Net Profit: $-2,769.11 Mln

        About The Company

        • IPO Date 16-Nov-2011
        • Co-Founder, CEO, Pres & Exec. Director Mr. Patrick J. Mahaffy MA
        • Exec. VP & CFO Mr. Daniel W. Muehl
        • Listing key-listing NASDAQ: CLVS
        • Country United States
        • Headquarters headquarters Boulder, CO
        • Website website https://www.clovisoncology.com
        • Business

          Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small...  molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3);and FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. In addition, the company sells its Rubraca through a limited number of specialty distributor and specialty pharmacy providers, who subsequently sells Rubraca to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, a clinical collaboration with Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado. On December 11, 2022, Clovis Oncology, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.  Read more

        share-fund-plan-icon